-
Mashup Score: 0Long-term Survival Observed in HIMALAYA Study of Durvalumab Plus Tremelimumab for uHCC - 7 month(s) ago
Home > Liver Cancer > Long-term Survival Observed in HIMALAYA Study of Durvalumab Plus Tremelimumab for uHCC Four-year follow-up data from the HIMALAYA trial showed that single tremelimumab regular interval durvalumab (STRIDE) improved overall survival (OS) and demonstrated a durable long-term survival benefit in patients with unresectable hepatocellular carcinoma (uHCC). The study was presented at th e Symposium on Clinical Interventional Oncology 2023. In this analysis, 1171 patients were randomized to
Source: docwirenews.comCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0Durvalumab Added to Standard of Care Improves Survival Outcomes for Patients With Muscle-Invasive Urothelial Carcinoma - 7 month(s) ago
According to a phase 2 trial, the additional of durvalumab to neoadjuvant chemotherapy and as an adjuvant treatment following surgery improved event-free survival and overall survival for patients with resectable, muscle-invasive urothelial carcinoma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to study investigators, “The addition of perioperative #durvalumab to the standard of care for patients with resectable [muscle-invasive urothelial carcinoma] results in high #EFS and #OS at 2 years.” Learn more: https://t.co/eLQP8Z4ozE #onctwitter #medtwitter https://t.co/0N1Ca2aChs
-
-
Mashup Score: 0
During a Targeted Oncology™ Case-Based Roundtable™ event, Edward S. Kim, MD, MBA, and participants discussed the PACIFIC and PACIFIC-R studies of durvalumab in patients with unresectable stage III non–small cell lung cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Edward S. Kim, MD, MBA, discussed the PACIFIC and PACIFIC-R studies of #durvalumab in patients with unresectable stage III #NSCLC. #lcsm | @cityofhope @DrEdKim https://t.co/tJluMKvfTL
-
-
Mashup Score: 1No Affect Seen With Anti-Drug Antibodies on Durvalumab Alone or With Tremelimumab in HCC - 12 month(s) ago
Anti-drug antibodies did not seem to affect how well the STRIDE regimen of durvalumab and tremelimumab or durvalumab alone worked in patients with unresectable hepatocellular carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to data from an analysis of the phase 3 HIMALAYA trial, anti-drug antibodies did not have an effect on the efficacy or safety of #durvalumab alone or the STRIDE combination of durvalumab + tremelimumab in #HCC. #lcsm https://t.co/tAnQaHuF02
-
-
Mashup Score: 0Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door? | Immunotherapy - 12 month(s) ago
Following the practice-changing results observed in several hematological and solid tumors, immunotherapy with immune checkpoint inhibitors (ICIs) has been tested in cholangiocarcinoma (CCA) patients. However, ICI monotherapy has had disappointing results in CCA, and phase I–III clinical trials have assessed whether combinatorial strategies including immunotherapy plus other anticancer agents may…
Source: ImmunotherapyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
5/7 📝Our guest editors, Drs. Rizzo and Ricci, along with their team, evaluated the drug durvalumab in advanced cholangiocarcinoma in their drug evaluation article🩺 #cancerresearch #durvalumab #cholangiocarcinoma https://t.co/F15XGWomeP
-
-
Mashup Score: 0
Promising efficacy has been seen with the use of immunotherapy for the management of patients with hepatocellular carcinoma, Now, durvalumab and tremelimumab combination therapy is being studied for this patient population listed for a liver transplant.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A phase 2 study is investigating #durvalumab and #tremelimumab for the treatment of patients with #HCC listed for a liver transplant. #lcsm https://t.co/fvrkZT592P
-
-
Mashup Score: 0
During a Targeted Oncology™ Case-Based Roundtable™ event, Richard Kim, MD, discussed regimens for biliary tract cancers including the results of the TOPAZ-1 trial of additional durvalumab.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
During a Targeted Oncology™ Case-Based Roundtable™ event, Richard Kim, MD, discussed regimens for #BTC, including the results of the TOPAZ-1 trial of additional #durvalumab. #gicsm | @MoffittNews https://t.co/mfcHRCDKqj https://t.co/nCV6dNOiCj
-
-
Mashup Score: 0
Osimertinib conferred a statistically significant and clinically meaningful improvement in OS compared with placebo among patients with early-stage EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer. Results of randomized, phase 3 ADAURA trial showed the survival benefit with osimertinib (Tagrisso, AstraZeneca), a third-generation, irreversible EGFR tyrosine
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Osimertinib extends survival in early EGFR-mutated non-small cell lung cancer. https://t.co/TpDAXuBxCN #Tagrisso @AstraZeneca #lungcancer #nonSmallCellLungCancer @YaleCancer #osimertinib #durvalumab #HemOnc
-
-
Mashup Score: 0Key Updates in the Changing NSCLC Treatment Landscape - 1 year(s) ago
In the third interview of this series, Edward B. Garon, MD, reviews the treatment landscape in non–small cell lung cancer, with a focus on immunotherapy and the recent approval of tremelimumab in combination with durvalumab and platinum-based chemotherapy.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Amidst the growing treatment landscape in #NSCLC, 1 of the most recent advancements was the approval of #tremelimumab in combination with #durvalumab and platinum-based chemotherapy for patients with advanced or metastatic disease. #lcsm @UCLAJCCC https://t.co/5G38r7QUFF
-
-
Mashup Score: 0Discussing When to Use Durvalumab in SCLC - 1 year(s) ago
Joshua K. Sabari, MD, discusses his use of durvalumab in the frontline setting for the treatment of patients with small-cell lung cancer and where he sees the role for the treatment.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Joshua K. Sabari, MD, explains his thoughts on the use of #durvalumab for patients with extensive-stage small cell lung cancer. #SCLC #lcsm | @nyulangone @JSabari https://t.co/m0RHhBHtC7
-
A study found that #durvalumab plus tremelimumab significantly improved overall survival in patients with unresectable liver cancer. #livercancer #gioncology #gicancer https://t.co/p0GzfsszCb https://t.co/McOqaCpadO